Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


November 3rd, 2023

Anteris Technologies Secures $40 Million in Capital Raise to Prepare for Pivotal Study

Novel heart valve development company Anteris Technologies (AVR: $20.00) has secured commitments to raise $40 million at $20 per share through a private placement.

October 3rd, 2023

Acquisition Targets for Australian Biotech Sector (Anteris Technologies)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

May 19th, 2023

Anteris Technologies - Expands Programs to Mitral and Tricuspid Valve Repair

Anteris Technologies (AVR: $23.00) finished the March quarter with $32 million in cash following a $35 million capital raise in the quarter at $24 per share. The company's net cash outflow for the last three quarters from operational and investment activities was $14.5 million.

April 6th, 2023

Anteris Technologies - Early Feasibility Study to Start Ahead of 1,000 Patient Pivotal Trial

Anteris Technologies (AVR: $21.50) is commercialising the DurAVR aortic heart valve which is implanted by catheter rather than open chest surgery. It is seeking to launch its product in coming years in a market estimated to be worth US$10 billion in 2028, based on only a 15%-20% penetration base of the current patients, according to CEO Wayne Paterson.

February 24th, 2023

Anteris Technologies Raises $35 Million

Aortic heart valve company Anteris Technologies (AVR: $21.71) has completed a $35 million capital raise, conducted at $24 per share. Investors also received a free two-year option to buy an additional share at $29.

December 18th, 2022

Anteris Technologies to Progress Heart Valve to Early Feasibility Study

Anteris Technologies (AVR: $23.20) is developing an aortic heart valve, called DurAVR THV. The device is implanted via a catheter rather than through open chest surgery and has delivered some impressive results compared to other valves implanted through the same process or through surgery.

Last month the company announced that it had reached agreement with the FDA on an early feasibility study to follow on from its first feasibility study in 13 patients. The early feasibility study will recruit 15 patients who will be implanted across seven implant centres in the US. It is only expected to take a few weeks to fully recruit.

October 5th, 2022

Anteris Technologies - Aortic Valve Outperforms Surgical and TAVR Competitors

Aortic heart valve company Anteris Technologies (AVR: $23.10) had multiple presentations at the major US conference TCT (Transcatheter Cardiovascular Therapeutics) held in Boston last month. The event has around 11,000 specialists in the field attending and was founded by Dr Martin Leon, who has joined the Anteris Medical Advisory Board earlier this year.

September 9th, 2022

Anteris Technologies to Present Key Data at TCT this Month

Anteris Technologies (AVR: $21.50) presented at the inaugural E&P Healthcare conference this week.

CEO Wayne Paterson believes that the technical risk for the company's novel aortic valve, the DurAVR 3D, has been significantly diminished, down to only 5%-10% following successful implantation into 13 patients. The remaining risk for the company relates primarily to execution.

Anteris is developing a single piece aortic valve that is implanted via catheter, rather than open-chest surgery.

August 19th, 2022

Anteris Technologies to Move to Pivotal Study as Positive Results Continue

For the six and 12 months to 30 June this year, medical device company Anteris Technologies (AVR: $24.60) has been the best performing stock, with a share price gain of 122% over the last six months and 310% over the financial year.

February 28th, 2022

Anteris Technologies Declines Merger Proposal

Aortic heart valve development company Anteris Technologies (AVR: $18.67) has declined a proposal to merge with US cashbox company Medicus Sciences Acquisition Corp.

February 14th, 2022

Anteris Technologies Declines Merger Proposal

Aortic heart valve development company Anteris Technologies (AVR: $18.67) has declined a proposal to merge with US cashbox company Medicus Sciences Acquisition Corp.